Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 49 points (0.3%) at 16,344 as of Tuesday, Dec. 24, 2013, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,931 issues advancing vs. 985 declining with 162 unchanged. The Drugs industry currently sits up 0.5% versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the industry include Actavis ( ACT), down 0.7%, Alexion Pharmaceuticals ( ALXN), down 0.6% and Amgen ( AMGN), down 0.5%. TheStreet would like to highlight 4 stocks pushing the industry lower today: 4. Isis Pharmaceuticals ( ISIS) is one of the companies pushing the Drugs industry lower today. As of noon trading, Isis Pharmaceuticals is down $0.98 (-2.4%) to $40.70 on light volume. Thus far, 275,809 shares of Isis Pharmaceuticals exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $40.30-$41.67 after having opened the day at $41.62 as compared to the previous trading day's close of $41.68. Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. Isis Pharmaceuticals has a market cap of $4.8 billion and is part of the health care sector. Shares are up 299.2% year to date as of the close of trading on Monday. Currently there are 3 analysts that rate Isis Pharmaceuticals a buy, 1 analyst rates it a sell, and 3 rate it a hold. TheStreet Ratings rates Isis Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full Isis Pharmaceuticals Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.